Per feedback from our community of oncologist members, Primum has added support for lung cancer virtual curbside consults.

‍

Why did we add lung cancer specialists?

‍

Approximately 240,000 lung cancer cases were forecasted to be diagnosed in 2022, comprising roughly 12% of all incident cancer cases.¹ This incidence translates to lung cancer being the 3rd most common form of cancer in the US. Despite, its relative commonality the 5-year survival rate of lung cancer is lower than other malignancies. For example, Multiple Myeloma has a 58% 5-year survival rate whereas the 5-year relative survival rate of lung cancer is ~23%². This lower survival rate highlights the fast-moving nature of lung cancer.

‍

Lung cancer treatment is an essential focus of community oncologists. The treatment paradigm is driven by using diagnostic tests to identify genetic mutations that can be targeted with chemotherapy. As a result, we’ve heard that Primum could assist when using the results of diagnostic tests to create a patient treatment plan. Also, Primum could be helpful when determining which therapeutic option to use given recent approvals, like the recent pembrolizumab approval (See links to Twitter discussion about this approval here and here).

‍

To answer lung cancer questions, Primum has added the following medical oncology specialists:

‍Dr. Mary Fidler

• Dr. Fidler is a Professor of Medicine at Rush Medical College. Her clinical focus is on the treatment of early and late-stage lung cancer patients. Her research focuses primarily on EGFR+ lung cancer, cancer cachexia, and predictive biomarkers.

‍

Dr. Goetz Kloecker, MBA, MSPH 

• Dr. Kloecker is the Director of Thoracic Medical Oncology at J. Graham Brown Cancer Center, UofL Health. He is clinically focused on multi-disciplinary treatment approaches for thoracic cancers. His research is focused on clinical trials of new chemotherapeutics and targeted agents.

‍

Dr. Raja Mudad 

• Dr. Mudad is a thoracic medical oncologist who is the Medical Director of Sylvester at Doral. He is clinically focused on lung cancer and other thoracic cancers like mesothelioma and thymoma.

‍

Dr. Mark Socinski

• Dr. Socinski is the Executive Medical Director of AdventHealth Cancer Institute. He specializes in all thoracic malignancies including NSCLC, SCLC, and mesothelioma.

‍

Additionally, Primum has added a number of thoracic radiation oncologists to answer community member questions:

Dr. Dwight Heron

• Dr. Heron is the System Medical Director for Oncology Services at Bon Secours Mercy Health. He is a radiation oncologist focused on lung, head and neck, breast, and CNS cancer treatment. He was previously the Director of Radiation Oncology for UPMC Hillman.

‍

Dr. Shruti Jolly

• Dr. Jolly is a Professor and the Associate Chair of Community Practices in the Department of Radiation Oncology at the University of Michigan. Her clinical focus is on the treatment of thoracic, gynecologic, and endocrine cancers.

‍

Types of inquiries our lung cancer specialists have received

‍

These specialists have provided advice to Primum community members across the following clinical scenarios:

• Would you add chemotherapy to IO in the setting of low-volume disease metastatic Adenocarcinoma of the lung with PDL-1 80%? Read Response
• 70 y/o with met. NSCLC has a good response to carbo/pen/pen but develops colitis on maintenance pembro. Excellent response to steroids but colitis recurs after taper. Got restarted on steroids and now starting on infliximab. Do you continue the steroids or stop/ taper them? Read Response

‍

To view more examples questions from Primum, check out our inquiries page or join the platform and enjoy our content library (login and select “Library”).

‍

Connect with lung cancer specialists on Primum

‍

Our lung cancer specialists are ready to receive your patient questions. They are able to answer patient-specific questions related to recurrence, toxicology, or comorbidity profiles. 

With Primum, you gain a trusted source of information near the point of care. We are excited to continue to work together to arm you with the best information possible as you care for your patients. Learn more here.

‍

Sources

1. Cancer Statistics, 2022 - https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21708
2. SEER Cancer Stat Facts: Lung and Bronchus Cancer - https://seer.cancer.gov/statfacts/html/lungb.html

‍

‍